The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution developed
by Danish specialist LEO Pharma. This injectable solution contains 300 mg of tralokinumab in a 2 mL pre-filled pen and will be available for tralokinumab patients
in the UK from early 2024.
Tralokinumab is indicated for treating moderate-to-severe atopic dermatitis in adult and adolescent patients aged 12 and older who require systemic therapy, Leo
Pharma said in a statement. It is a fully human monoclonal antibody developed to specifically bind to and inhibit the IL-13 cytokine. Previously, it was available
in a 150 mg in 1 mL pre-filled syringe.
According to Leo Pharma, the 300 mg tralokinumab in a 2 mL pre-filled pen offers a streamlined administration for both patients and prescribers. It begins with an
initial 600 mg dose in two injections, followed by a single 300 mg maintenance dose administered every other week.
"We're pleased that this simplified administration method for tralokinumab will soon benefit eligible atopic dermatitis patients in the UK. It aligns with our
commitment to elevate the standard of care and support for individuals with skin conditions," said Leanne Walsh, Vice President and General Manager of UK and
Ireland at LEO Pharma.
Eczema (atopic dermatitis), which affects up to 20 per cent of children, is one of the most common conditions pharmacists encounter, but don't underestimate
eczema. Generalised eczema may compromise health-related quality of life (HRQoL) more than several other chronic diseases, including asthma, epilepsy and diabetes.
Despite the impact on HRQoL, underuse of moisturisers and topical corticosteroids often leaves childhood eczema poorly controlled.
UK researchers recently reported that several factors contribute to the underuse of moisturisers and topical corticosteroids in children with eczema. For instance,
most of the 30 parents and carers interviewed felt that they had received little information about eczema.
The lack of understanding may help explain why some parents and carers expressed concerns, such as the risk of skin thinning, about topical corticosteroids. Some
were not convinced that moisturisers (strictly, an emollient is an ingredient of a moisturiser) reduced itch and maintained control of eczema. Some felt that
moisturisers' efficacy declined over time.
Parents and carers also admitted to "incomplete knowledge and skills" about managing eczema (such as whether they should apply moisturisers regularly) and
reluctance to manage eczema in collaboration with their child. Parents and carers wanted advice about using treatments and explanations of moisturisers' and
topical corticosteroids' mechanisms of action. The authors note that healthcare professionals could help identify and address gaps in knowledge.